An international consortium of researchers has unveiled a transformative approach to agricultural biotechnology that could fundamentally alter the landscape of…
Read More
TWiV 1284: Clinical Update with Dr. Daniel Griffin and Vincent Racaniello Focuses on Resurgent Infectious Diseases and Evidence-Based Practice
The landscape of public health in the United States faces a complex array of challenges as the medical community navigates…
Read More
Eli Lilly and InnoCare Pharma Forge $3.35bn R&D Partnership to Tackle Oncology and Autoimmune Diseases
Eli Lilly and Company has entered into a sweeping, five-drug research and licensing agreement with China-based biopharmaceutical firm InnoCare Pharma,…
Read More
The Paradigm Shift in Healthcare: How Cell and Gene Therapies Are Redefining the Treatment of Rare Diseases
Rare diseases have long presented one of the most stubborn and heartbreaking frontiers in modern medicine. Historically characterized by profound…
Read More
RNA breakthrough provides hope for thousands of untreatable diseases, including cystic fibrosis, muscular dystrophy and some cancers
A multi-institutional team of researchers at the University of Toronto has unveiled a next-generation RNA therapeutic platform designed to target…
Read More
Exploring the Cutting Edge: New eBook Dives into Single-Cell Spatial Omics, Cancer, Neurodevelopmental Diseases, and AI in Biomedical Research
The newly released eBook, supported by Takara Bio, offers an in-depth exploration into the revolutionary advancements shaping the field of…
Read More
Tubulin Identified as a Critical Molecular Safeguard Against Neurodegenerative Protein Aggregation in Alzheimer’s and Parkinson’s Diseases
Scientists at the Baylor College of Medicine have announced a landmark discovery in the field of neurobiology, identifying a novel…
Read More
Immunai and Boehringer Ingelheim Forge Strategic Alliance to Uncover Novel T-Cell Targets in Oncology and Autoimmune Diseases
Immunai, a leading artificial intelligence (AI) company specializing in immune system analysis, and Boehringer Ingelheim, a global biopharmaceutical giant, have…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Rethinking evidence generation for ultra-rare diseases
Developing treatments for ultra-rare diseases presents fundamental challenges for traditional evidence generation, necessitating a paradigm shift in how scientific rigor…
Read More
